Prevalence of antibody positivity to SARS-CoV-2 following the first peak of infection in England : Serial cross-sectional studies of 365,000 adults
© 2021 The Author(s)..
BACKGROUND: The time-concentrated nature of the first wave of the COVID-19 epidemic in England in March and April 2020 provides a natural experiment to measure changes in antibody positivity at the population level before onset of the second wave and initiation of the vaccination programme.
METHODS: Three cross-sectional national surveys with non-overlapping random samples of the population in England undertaken between late June and September 2020 (REACT-2 study). 365,104 adults completed questionnaires and self-administered lateral flow immunoassay (LFIA) tests for IgG against SARS-CoV-2.
FINDINGS: Overall, 17,576 people had detectable antibodies, a prevalence of 4.9% (95% confidence intervals 4.9, 5.0) when adjusted for test characteristics and weighted to the adult population of England. The prevalence declined from 6.0% (5.8, 6.1), to 4.8% (4.7, 5.0) and 4.4% (4.3, 4.5), over the three rounds of the study a difference of -26.5% (-29.0, -23.8). The highest prevalence and smallest overall decline in positivity was in the youngest age group (18-24 years) at -14.9% (-21.6, -8.1), and lowest prevalence and largest decline in the oldest group (>74 years) at -39.0% (-50.8, -27.2). The decline from June to September 2020 was largest in those who did not report a history of COVID-19 at -64.0% (-75.6, -52.3), compared to -22.3% (-27.0, -17.7) in those with SARS-CoV-2 infection confirmed on PCR.
INTERPRETATION: A large proportion of the population remained susceptible to SARS-CoV-2 infection in England based on naturally acquired immunity from the first wave. Widespread vaccination is needed to confer immunity and control the epidemic at population level.
FUNDING: This work was funded by the Department of Health and Social Care in England.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:4 |
|---|---|
| Enthalten in: |
The Lancet regional health. Europe - 4(2021) vom: 01. Mai, Seite 100098 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ward, Helen [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 14.02.2024 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.lanepe.2021.100098 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM325209871 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM325209871 | ||
| 003 | DE-627 | ||
| 005 | 20240214232313.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.lanepe.2021.100098 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1292.xml |
| 035 | |a (DE-627)NLM325209871 | ||
| 035 | |a (NLM)33969335 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ward, Helen |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Prevalence of antibody positivity to SARS-CoV-2 following the first peak of infection in England |b Serial cross-sectional studies of 365,000 adults |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 14.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2021 The Author(s). | ||
| 520 | |a BACKGROUND: The time-concentrated nature of the first wave of the COVID-19 epidemic in England in March and April 2020 provides a natural experiment to measure changes in antibody positivity at the population level before onset of the second wave and initiation of the vaccination programme | ||
| 520 | |a METHODS: Three cross-sectional national surveys with non-overlapping random samples of the population in England undertaken between late June and September 2020 (REACT-2 study). 365,104 adults completed questionnaires and self-administered lateral flow immunoassay (LFIA) tests for IgG against SARS-CoV-2 | ||
| 520 | |a FINDINGS: Overall, 17,576 people had detectable antibodies, a prevalence of 4.9% (95% confidence intervals 4.9, 5.0) when adjusted for test characteristics and weighted to the adult population of England. The prevalence declined from 6.0% (5.8, 6.1), to 4.8% (4.7, 5.0) and 4.4% (4.3, 4.5), over the three rounds of the study a difference of -26.5% (-29.0, -23.8). The highest prevalence and smallest overall decline in positivity was in the youngest age group (18-24 years) at -14.9% (-21.6, -8.1), and lowest prevalence and largest decline in the oldest group (>74 years) at -39.0% (-50.8, -27.2). The decline from June to September 2020 was largest in those who did not report a history of COVID-19 at -64.0% (-75.6, -52.3), compared to -22.3% (-27.0, -17.7) in those with SARS-CoV-2 infection confirmed on PCR | ||
| 520 | |a INTERPRETATION: A large proportion of the population remained susceptible to SARS-CoV-2 infection in England based on naturally acquired immunity from the first wave. Widespread vaccination is needed to confer immunity and control the epidemic at population level | ||
| 520 | |a FUNDING: This work was funded by the Department of Health and Social Care in England | ||
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Cooke, Graham S |e verfasserin |4 aut | |
| 700 | 1 | |a Atchison, Christina |e verfasserin |4 aut | |
| 700 | 1 | |a Whitaker, Matthew |e verfasserin |4 aut | |
| 700 | 1 | |a Elliott, Joshua |e verfasserin |4 aut | |
| 700 | 1 | |a Moshe, Maya |e verfasserin |4 aut | |
| 700 | 1 | |a Brown, Jonathan C |e verfasserin |4 aut | |
| 700 | 1 | |a Flower, Barnaby |e verfasserin |4 aut | |
| 700 | 1 | |a Daunt, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Ainslie, Kylie |e verfasserin |4 aut | |
| 700 | 1 | |a Ashby, Deborah |e verfasserin |4 aut | |
| 700 | 1 | |a Donnelly, Christl A |e verfasserin |4 aut | |
| 700 | 1 | |a Riley, Steven |e verfasserin |4 aut | |
| 700 | 1 | |a Darzi, Ara |e verfasserin |4 aut | |
| 700 | 1 | |a Barclay, Wendy |e verfasserin |4 aut | |
| 700 | 1 | |a Elliott, Paul |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Lancet regional health. Europe |d 2021 |g 4(2021) vom: 01. Mai, Seite 100098 |w (DE-627)NLM323979734 |x 2666-7762 |7 nnns |
| 773 | 1 | 8 | |g volume:4 |g year:2021 |g day:01 |g month:05 |g pages:100098 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.lanepe.2021.100098 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 4 |j 2021 |b 01 |c 05 |h 100098 | ||